ALXN 1007

Drug Profile

ALXN 1007

Alternative Names: ALXN-1007

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Alexion Pharmaceuticals
  • Class Anti-inflammatories; Antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Antiphospholipid syndrome; Graft-versus-host disease
  • Phase I Inflammation

Most Recent Events

  • 15 Mar 2017 Alexion Pharmaceuticals terminates a phase-II trial in Graft-versus-host disease (Newly diagnosed) in France and USA (NCT02245412)
  • 19 Oct 2016 ALXN 1007 receives Orphan Drug status for Graft-versus-host disease in USA
  • 31 Aug 2016 Phase-II clinical trials in Antiphospholipid syndrome in Italy (IV) (NCT02128269) before August 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top